ESTRO PT 2018

H-N Phase II/III Randomized Trial (MDACC) Oropharyngeal Cancer - IMPT vs IMRT

Tremendous effort to conduct this trial.

IMPT (70 Gy(RBE)) Chemotherapy (locally advanced disease)

R A N D O M I Z A T I O N

IMRT (70 Gy) Chemotherapy (locally advanced disease) Then this trial could be 76 Gy(RBE) versus 70 Gy photons and yield much more information. Treatment 33 days If Phase II trials would have been done first – maybe they would have shown that 76 Gy(RBE) of protons can safely be delivered AND result in superior local control. PROs Recovery 10 wks Restaging Surgery No Surgery

Eligibility

Follow-up

1) Stage III-IV

oropharyngeal cancer

PROs Q3 mo

2) Squamous cell carcinoma

3) ECOG<2

Follow-up

4) Target volume delineation

PROs Q3 mo

Primary endpoint: CTC-AE G3+ toxicity at 90 days – 2 years

Frank – PI Trial Activated – Sept 2013

Courtesy Steve Frank